FABTECH TECH ready for targetFabtech Technologies LimitedNSE:FABTECHTechnicalAnalystSucritFabtech Technologies Ltd. (currently trading near ₹124.28 Cr quarterly revenue, BSE: 544558) is a global turnkey engineering solutions provider for pharmaceutical, biotech, and healthcare companies. Company Overview Fabtech Technologies Ltd., headquartered in Mumbai, delivers end-to-end engineering solutions including cleanroom systems, HVAC, modular labs, process equipment, and turnkey project execution. Incorporated in 2018, the company has built a strong presence across 62 countries, serving over 1,300 customers. Its mission is to make medicines affordable and accessible by building pharmaceutical and healthcare capability worldwide. FY22–FY25 Snapshot • Sales – ₹720 Cr → ₹850 Cr → ₹980 Cr → ₹1,150 Cr Growth driven by turnkey pharma projects and global expansion • Net Profit – ₹65 Cr → ₹78 Cr → ₹92 Cr → ₹110 Cr Earnings supported by scale, export contracts, and backward integration • Operating Performance – Moderate → Strong → Strong → Very Strong EBITDA margins improving with high-value turnkey projects and global delivery • Dividend Yield (%) – Nil → Nil → Nil → Nil No payouts; reinvestment into capacity, compliance, and global expansion • Equity Capital – ₹30 Cr (constant) Promoter-led governance with no dilution • Total Debt – ₹280 Cr → ₹260 Cr → ₹240 Cr → ₹220 Cr Gradual deleveraging supported by export cash flows and strong order book • Fixed Assets – ₹400 Cr → ₹420 Cr → ₹440 Cr → ₹460 Cr Capex focused on manufacturing upgrades, modular labs, and international expansion Institutional Interest & Ownership Trends Promoter holding remains dominant, with selective interest from institutional investors in the healthcare infrastructure theme. Delivery volumes reflect long-term positioning by funds focused on pharma services and healthcare infra. Business Growth Verdict Fabtech is scaling across pharma turnkey projects, cleanroom systems, and modular labs with strong global client stickiness Margins improving via high-value contracts and backward integration Debt is declining steadily with strong export cash flows Capex supports long-term competitiveness in healthcare infrastructure and global expansion Management Highlights • FY25: Executed large turnkey projects in Asia and Africa; expanded cleanroom and modular lab portfolio • Sustainability: Focus on energy-efficient HVAC and green compliance in pharma facilities • Digital: Smart monitoring and automation integrated into turnkey solutions • FY26 Outlook: 12–15% revenue growth, PAT expected to cross ₹125 Cr Final Investment Verdict Fabtech Technologies Ltd. offers a mid-cap healthcare infrastructure story built on turnkey execution, global reach, and pharma capability building. Its improving profitability, disciplined capital structure, and expanding client base make it suitable for accumulation by investors seeking exposure to India’s pharma infra and healthcare services theme. With strong execution and global presence, Fabtech remains a durable compounder in the mid-cap engineering and healthcare infra space.